Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer-a real-world experience.

Nandini Devi, R; Praveen Kumar Shenoy, V P; Ismail, Irshad; Avaronnan, Manuprasad

Nandini Devi, R; Praveen Kumar Shenoy, V P; Ismail, Irshad; Avaronnan, Manuprasad.

Afiliação

Nandini Devi R; Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Thalassery, Kannur 670103, India.
Praveen Kumar Shenoy VP; Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Thalassery, Kannur 670103, India.
Ismail I; Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Thalassery, Kannur 670103, India.
Avaronnan M; Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Thalassery, Kannur 670103, India.

Ecancermedicalscience ; 17: 1589, 2023.

Article em En | MEDLINE | ID: mdl-37799959

Palavras-chave

Fosfestrol; LMIC; castration-resistant prostate cancer; hormonal therapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Ecancermedicalscience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google